Literature DB >> 3264194

Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system.

R Delwel1, M Salem, C Pellens, L Dorssers, G Wagemaker, S Clark, B Löwenberg.   

Abstract

The response of human acute myeloid leukemia (AML) cells to the distinct hematopoietic growth factors (HGFs), ie, recombinant interleukin-3 (IL-3), granulocyte-macrophage-CSF (GM-CSF), granulocyte-CSF (G-CSF), macrophage-CSF (M-CSF), and erythropoietin (Epo) was investigated under well-defined serum-free conditions. Proliferative responses to these factors, when added separately as well as in combinations, were analyzed in 25 cases of human AML using 3H-thymidine incorporation and colony assays. The 3H-thymidine uptake data revealed that IL-3, GM-CSF, G-CSF, and M-CSF were stimulators of AML proliferation in 19, 15, 13, and 4 cases, respectively. Epo only stimulated DNA synthesis in the cells of the single erythroleukemia case. GM-CSF stimulation was seen only in IL-3 reactive cases and GM-CSF, when combined with IL-3, could not further elevate the DNA synthesis evoked by IL-3 alone. On the other hand, in six cases, G-CSF enhanced the IL-3- or GM-CSF-stimulated thymidine uptake. These results suggest that subpopulations of AML cells that are activated by distinct CSFs (eg, IL-3/GM-CSF-responsive cells and G-CSF-responsive cells) coexist. The 3H-thymidine incorporation assay was more sensitive for measuring CSF responses than methylcellulose colony cultures, since activation of DNA synthesis was more frequently seen than induction of colony formation. DNA synthesis experiments revealed eight different CSF response patterns among these 25 cases. CSF phenotyping may be a useful addition to the morphologic classification of AML, since these patterns directly reflect the ability of the proliferating subsets of AML cells to respond to the CSFs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264194

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  G-CSF: status quo and new indications.

Authors:  F Herrmann
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

Review 2.  Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.

Authors:  G Schwab; T Hecht
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

3.  Granulocyte colony-stimulating factor (G-CSF) treatment in a neutropenic leukemia patient with diffuse interstitial pulmonary infiltrates.

Authors:  A Heyll; C Aul; F Gogolin; M Thomas; M Arning; A Gehrt; U Hadding
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

4.  Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF) : A Review of its Pharmacological Properties and Prospective Role in the Management of Myelosuppression.

Authors:  Susan M Grant; Rennie C Heel
Journal:  Drugs       Date:  1992-04       Impact factor: 9.546

Review 5.  Colony-stimulating factors in the treatment of older patients with acute myelogenous leukaemia.

Authors:  S Bolam; T Hamblin
Journal:  Drugs Aging       Date:  1999-12       Impact factor: 3.923

Review 6.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

7.  A newly developed serum-free culture system: clonal growth of human acute myelogeneous leukemia (AML) progenitors--a report of 14 AML cases.

Authors:  J S Tang; B M Wang; C Y Li
Journal:  J Tongji Med Univ       Date:  1994

8.  Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.

Authors:  G Visani; D Damiani; A Cenacchi; D Russo; G Revignas; B Gamberi; R Fanin; M Fogli; M Baccarani; S Tura
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

9.  Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors.

Authors:  G Visani; M Fogli; P Tosi; E Ottaviani; B Gamberi; A Cenacchi; S Manfroi; S Tura
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

10.  Granulocyte colony stimulating factor increases drug resistance of leukaemic blast cells to daunorubicin.

Authors:  László Márkász; György Hajas; Andrea Kiss; Beáta Lontay; Eva Rajnavölgyi; Ferenc Erdodi; Eva Oláh
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.